FOXF2 and breast cancer: According to a study published by Wang Shuo et al., in 2019, FOXF2 can promote the epithelium-to-osteomimicry transition (EOT) of breast cancer cells by activating BMP4/Smad1 signaling pathway, thus reprogramming them into bone metastasis seeds, and ultimately promoting the bone metastasis tendency of cancer cells [47].